#USA #Phoenix #T-cell Engager #Immunofoco #SITC 2026

Immunofoco's Revolutionary T-Cell Engager Delivery Strategy

At the recently concluded 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2026) held from November 4 to 8 in Phoenix, Arizona, Immunofoco introduced a novel strategy for T-cell engager (TCE) delivery that could dramatically enhance cancer treatment efficacy. This development represents a significant step in immunotherapy, harnessing the potential to engineer tumor cells for sustained T-cell activation and tumor elimination.

Background

T-cell engaging therapies, especially those targeting onco-immune interactions, have shown considerable promise in treating B-cell malignancies. The challenges, however, remain significant; many current therapies suffer from limited serum half-lives and necessitate continuous administration, which can lead to various treatment-related toxicities. Recognizing these barriers, Immunofoco's team collaborated with esteemed institutions including Renji Hospital and Shanghai Jiao Tong University to pioneer this advanced delivery mechanism.

Engineering a Solution

The proposed method involves using CD19-targeted lentiviral vectors that genetically reprogram lymphoma cells to act as factories for producing bispecific T-cell engagers (BiTEs). By equipping these cells with the ability to continuously secrete CD3×CD19 BiTEs, the therapy enhances T-cell engagement within the tumor microenvironment. This sustained local secretion aims to improve the overall efficacy of the immunotherapeutic approach.

The critical work was encapsulated in a poster titled "Engineering lymphoma cells as in situ CD3×CD19 BiTE factories via CD19-targeted lentiviral delivery enables sustained T-cell engagement and tumor elimination." This title reflects not only the innovative approach but also the thoroughness of the research.

Study and Results

To validate their strategy, Immunofoco's researchers initiated a comprehensive study evaluating the transduction efficiency of the lentiviral vectors in various experimental models. They observed impressive rates of transduction, approximately 9-18% in Raji cells and 15-29% in Nalm6 cells, just two days post-infection. The engineered cells demonstrated a remarkable capacity to secrete functional BiTEs, achieving peak concentrations of approximately 300 pg/mL.

Perhaps most promising were the in vivo results. In experiments conducted on Nalm6-Luc-bearing NSG mice that received human peripheral blood mononuclear cells (PBMCs), the mice underwent treatment with the CD19-targeted BiTE virus. The outcome was significantly favorable, showing durable tumor clearance with bioluminescence signals returning near baseline levels for over 58 days. In stark contrast, a control group treated with blinatumomab, a conventional BiTE protein therapy, showed frequent tumor relapses.

Implications and Future Directions

This groundbreaking study suggests that the dual-engine cell therapy platforms, which combine both autologous CAR-T and in vivo CAR-T therapies, can lead to more effective treatment regimens for B-cell malignancies. Immunofoco aims to continue its exploration of these technologies further, targeting their applications across different disease contexts.

As the company advances these innovative therapeutic strategies, the implications for treatment of B-cell malignancies are profound. The potential for improved patient outcomes hinges not only on addressing the limitations of current therapies but also on pioneering methods that enhance localized treatment efficacy.

Conclusion

Immunofoco's presentation at SITC 2026 provides a strong foundation for the future of T-cell therapy. Their approach may well revolutionize the landscape of B-cell malignancy treatment, promising more effective and durable immunotherapeutic responses, ultimately enhancing the quality of life for countless patients navigating the challenges of cancer.

As developments in immunotherapy continue to progress, further research and validation will be essential in transforming these innovative strategies into clinical reality. Only time will tell how such advancements will reshape cancer treatment in the years to come.